Corticosteroids in brain cancer patients: benefits and pitfalls
暂无分享,去创建一个
[1] M. Weller,et al. Steroids in neurooncology: actions, indications, side-effects. , 2010, Current opinion in neurology.
[2] C. Pui,et al. Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.
[3] D. Furst,et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.
[4] J. Tuckermann,et al. The role of the glucocorticoid receptor in inflammation and immunity , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[5] A. Carpentier,et al. Steroid requirements during radiotherapy for malignant gliomas , 2010, Journal of Neuro-Oncology.
[6] G. Chrousos,et al. The human glucocorticoid receptor: Molecular basis of biologic function , 2010, Steroids.
[7] D. Kondziolka,et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.
[8] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Patrick Y Wen,et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Jain,et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.
[11] C. Förster,et al. Glucocorticoids Increase VE-Cadherin Expression and Cause Cytoskeletal Rearrangements in Murine Brain Endothelial cEND Cells , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[12] G. Pond,et al. The use and toxicity of steroids in the management of patients with brain metastases , 2008, Supportive Care in Cancer.
[13] A. Storch,et al. Dexamethasone blocks astroglial differentiation from neural precursor cells , 2006, Neuroreport.
[14] J. Haorah,et al. Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.
[15] P. Wen,et al. Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.
[16] M. Sundberg,et al. Glucocorticoid Hormones Decrease Proliferation of Embryonic Neural Stem Cells through Ubiquitin-Mediated Degradation of Cyclin D1 , 2006, The Journal of Neuroscience.
[17] G. Goozée,et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[18] H. Reichardt,et al. Glucocorticoids in T cell apoptosis and function , 2005, Cellular and Molecular Life Sciences.
[19] P. Barnes. Molecular mechanisms and cellular effects of glucocorticosteroids. , 2005, Immunology and allergy clinics of North America.
[20] C. Förster,et al. Occludin as direct target for glucocorticoid‐induced improvement of blood–brain barrier properties in a murine in vitro system , 2005, The Journal of physiology.
[21] A. Lipton. New therapeutic agents for the treatment of bone diseases , 2005, Expert opinion on biological therapy.
[22] Rolando F. Del Maestro,et al. Effect of steroids on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography , 2005, Journal of Neuro-Oncology.
[23] I. Adcock,et al. [Molecular mechanisms of glucocorticoids]. , 2005, Archivos de bronconeumologia.
[24] J. Owczarek,et al. Drug-induced myopathies. An overview of the possible mechanisms. , 2005, Pharmacological reports : PR.
[25] M. C. Papadopoulos,et al. Molecular mechanisms of brain tumor edema , 2004, Neuroscience.
[26] N. Banik,et al. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities , 2004, Molecular Cancer.
[27] H. Son,et al. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro , 2004, Brain Research.
[28] H. Son,et al. Differential effects of corticosterone and dexamethasone on hippocampal neurogenesis in vitro. , 2004, Biochemical and biophysical research communications.
[29] N. Nathoo,et al. The eicosanoid cascade: possible role in gliomas and meningiomas , 2003, Journal of clinical pathology.
[30] K. Plate,et al. VEGF in Brain Tumors , 2000, Journal of Neuro-Oncology.
[31] D. Schiff. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features , 1996, Journal of Neuro-Oncology.
[32] H. Knüpfer,et al. Time-dependent Inhibition of Glioblastoma Cell Proliferation by Dexamethasone , 2004, Journal of Neuro-Oncology.
[33] S. Grossman,et al. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. , 2003, Cancer treatment reviews.
[34] J. Cidlowski,et al. Molecular mechanisms of glucocorticoid action and resistance , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[35] S. Rüegg. Dexamethasone/phenytoin interactions: neurooncological concerns. , 2002, Swiss medical weekly.
[36] M. Perretti,et al. Regulation of Leukocyte‐Endothelial Interactions by Glucocorticoids , 2002, Annals of the New York Academy of Sciences.
[37] K. Carson,et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. , 2002, Neuro-oncology.
[38] K. Chihara,et al. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells , 2001, Neuroscience Letters.
[39] M. Hochberg,et al. Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .
[40] D. Franchimont,et al. Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 , 2000, The Journal of Immunology.
[41] H. Cohen,et al. Cognitive decline in patients with Cushing's syndrome , 2000, Journal of the International Neuropsychological Society.
[42] M. Westphal,et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas , 1999, International Journal of Developmental Neuroscience.
[43] C. Riccardi,et al. Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. , 1999, Blood.
[44] T. Hander,et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] E. Papavassiliou,et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. , 1996, The Journal of clinical investigation.
[46] L. Deangelis,et al. Medical management of cerebral metastases. , 1996, Neurosurgery clinics of North America.
[47] R. Blasberg,et al. Corticotropin-releasing factor decreases vasogenic brain edema. , 1996, Cancer research.
[48] Koehler Pj. Use of corticosteroids in neuro-oncology. , 1995 .
[49] P. Koehler. Use of corticosteroids in neuro-oncology. , 1995, Anti-cancer drugs.
[50] K. Whyte,et al. Discrimination against people with HIVinfection and AIDS , 1994, BMJ.
[51] W. van Putten,et al. Dose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors , 1994, Neurology.
[52] K. Sepkowitz,et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.
[53] B. Strom,et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. , 1991, The American journal of medicine.
[54] S. Soong,et al. Steroid‐induced weakness in patients with primary brain tumors , 1991, Neurology.
[55] J. G. Quintrec,et al. Drug-induced myopathies. , 1991, Bailliere's clinical rheumatology.
[56] J. Henson,et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. , 1991, Archives of neurology.
[57] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Ahmed Ar,et al. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989 .
[59] A. Ahmed,et al. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989, Annals of allergy.
[60] M. Sogin,et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi , 1988, Nature.
[61] N. Vick. Steroid toxicity. , 1988, Journal of neuro-oncology.
[62] R. Ruff,et al. Endocrine myopathies. , 1988, Neurologic clinics.
[63] J. Best,et al. BRAIN WATER MEASURED BY MAGNETIC RESONANCE IMAGING Correlation with Direct Estimation and Changes After Mannitol and Dexamethasone , 1987, The Lancet.
[64] M. Frame,et al. Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents. , 1986, Anticancer research.
[65] C. Miller,et al. Steroid-induced remission in primary malignant lymphoma of the central nervous system. , 1986, Surgical neurology.
[66] D. Goldspink,et al. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle , 1986, Muscle & nerve.
[67] E. Hedley‐Whyte,et al. Effect of dexamethasone on blood-brain barrier in the normal mouse. , 1986, Annals of neurology.
[68] T. Poynard,et al. Adrenocorticosteroid administration and peptic ulcer: a critical analysis. , 1985, Journal of chronic diseases.
[69] M. Eadie,et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[70] D. Ettinger,et al. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. , 1984, The New England journal of medicine.
[71] H. M. Bartkowski. Peritumoral edema. , 1984, Progress in experimental tumor research.
[72] R. Layzer. Neuromuscular manifestations of systemic disease , 1984 .
[73] M. Newmark,et al. Drug Spotlight Program: The Use of Antiepileptic Drugs , 1979 .
[74] M. Newmark,et al. The use of antiepileptic drugs. , 1979, Annals of internal medicine.
[75] J. Miller,et al. Methylprednisolone treatment in patients with brain tumors. , 1977, Neurosurgery.
[76] R. Moskowitz,et al. Steroid myopathy in connective tissue disease. , 1976, The American journal of medicine.
[77] H O Conn,et al. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. , 1976, The New England journal of medicine.
[78] J. Miller,et al. Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients. , 1975, Journal of neurosurgery.
[79] P. Gutin. Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. , 1975, Seminars in oncology.
[80] C. Koski,et al. Oxidative metabolism of skeletal muscle in steroid atrophy. , 1974, Archives of neurology.
[81] E. Werk,et al. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. , 1972, The Journal of clinical endocrinology and metabolism.
[82] E. Werk,et al. Effect of diphenylhydantoin on cortisol kinetics in humans. , 1971, The Journal of pharmacology and experimental therapeutics.
[83] J. Melby,et al. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. , 1961, The Journal-lancet.
[84] S. Taylor,et al. Treatment of cerebral metastases from breast carcinoma with prednisolone. , 1957, Journal of the American Medical Association.
[85] R. Mclaurin,et al. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. , 1952, The New England journal of medicine.